Table 4. Subgroup analysis of overall quality of life and domains among patients with secreting tumors who achieved endocrine remission vs. those who did not ( N  = 22); non-secreting tumors who achieved gross tumor resection vs. those who did not ( N  = 27) and combined group of patients with non-secreting tumors who achieved gross tumor resection and patients with secreting tumors who achieved endocrine remission vs. those who did not ( N  = 49) .

		SNOT-22	Overall ASBS-Q score	Emotional state	Specific symptoms	Pain	Vitality	Physical function	Role of performance
No endocrine remission ( n  = 4)	Preop ( n  = 4)	21.25 ± 12.92	4.48 ± 0.32	4.35 ± 0.44	4.58 ± 0.29	4.25 ± 0.5	4.58 ± 0.35	4.54 ± 0.54	4.36 ± 0.35
	After 2 mo ( n  = 3)	24.67 ± 19.35	4.09 ± 0.55	4.13 ± 0.81	4.0 ± 0.50	3.78 ± 0.38	4.38 ± 0.40	4.21 ± 0.76	3.84 ± 0.61
	After 4–6 mo ( n  = 2)	24.5 ± 34.65	4.7 ± 0.14	5 ± 0	4.42 ± 0.82	4.67 ± 0.47	4.9 ± 0.14	4.93 ± 0.1	4.56 ± 0.09
With endocrine remission ( n  = 18)	Preop ( n  = 18)	20.82 ± 15.50	4.04 ± 0.72	3.47 ± 1.06	4.22 ± 0.63	3.87 ± 1.31	3.76 ± 1.18	4.42 ± 0.75	4.13 ± 0.85
	After 2 mo ( n  = 14)	11.15 ± 13.86	4.38 ± 0.71	4.25 ± 1.0	4.4  ±  0.60	4.52 ± 0.58	4.2 ± 1.11	4.53 ± 0.70	4.37 ± 0.82
	After 4–6 mo ( n  = 12)	24.5 ± 21.57	4.34 ± 0.58	3.95 ± 1.15	4.26 ± 0.77	4.33 ± 0.91	4 ± 0.95	4.77 ± 0.3	4.41 ± 0.45
No GTR ( n  = 8)	Preop ( n  = 8)	15.43 ± 15.41	4.3 ± 0.72	4.01 ± 1.26	4.35 ± 0.46	4.04 ± 1.09	4.6 ± 0.54	4.39 ± 0.80	4.14 ± 1.11
	After 2 mo ( n  = 7)	22 ± 18.92	4.29 ± 0.744	4.0 ± 1.04	4.38 ± 0.79	3.80 ± 1.38	4.51 ± 0.68	4.42 ± 0.61	4.3 ± 0.72
	After 4–6 mo ( n  = 3)	18.83 ± 10.42	4.41 ± 0.43	4.38 ± 0.51	4.41 ± 0.25	4.33 ± 1.15	4.75 ± 0.13	4.33 ± 0.81	4.18 ± 0.80
With GTR ( n  = 19)	Preop ( n  = 19)	17.78 ± 16.5	4.33 ± 0.59	4.09 ± 0.94	4.43 ± 0.59	4.28 ± 0.28	4.27 ± 0.73	4.55 ± 0.58	4.27 ± 0.66
	After 2 mo ( n  = 18)	16.05 ± 15.92	4.5 ± 0.54	4.51 ± 0.60	4.34 ± 0.73	4.35 ± 0.71	4.52 ± 0.55	4.66 ± 0.60	4.51 ± 0.56
	After 4–6 mo ( n  = 10)	13.22 ± 8.52	4.58 ± 0.42	4.41 ± 0.79	4.43 ± 0.62	4.7 ± 0.53	4.71 ± 0.34	4.71 ± 0.28	4.54 ± 0.47
No success ( n  = 12)	Preop ( n  = 12)	17.55 ± 14.19	4.36 ± 0.61	4.13 ± 1.05	4.43 ± 0.42	4.11 ± 0.91	4.59 ± 0.47	4.44 ± 0.71	4.22 ± 0.91
	After 2 mo ( n  = 10)	22.80 ± 17.99	4.23 ± 0.67	4.04 ± 0.94	4.27 ± 0.72	3.80 ± 1.15	4.48 ± 0.50	4.37 ± 0.63	4.16 ± 0.70
	After 4–6 mo ( n =)	21.10 ± 19.08	4.53 ± 0.35	4.54 ± 0.52	4.42 ± 0.45	4.47 ± 0.87	4.81 ± 0.14	4.57 ± 0.66	4.34 ± 0.61
Success ( n  = 37)	Preop ( n  = 37)	19.26 ± 15.86	4.19 ± 0.67	3.79 ± 1.04	4.33 ± 0.61	4.08 ± 1.10	4.02 ± 0.99	4.49 ± 0.67	4.20 ± 0.75
	After 2 mo ( n  = 32)	14 ± 15.06	4.45 ± 0.61	4.40 ± 0.80	4.37 ± 0.67	4.43 ± 0.65	4.38 ± 0.90	4.61 ± 0.64	4.45 ± 0.68
	After 4–6 mo ( n =)	19.67 ± 17.82	4.45 ± 0.52	4.17 ± 1.00	4.34 ± 0.69	4.51 ± 0.76	4.34 ± 0.80	4.75 ± 0.29	4.48 ± 0.45

Abbreviations: CSF, cerebrospinal fluids; GTR, gross tumor resection; NSF, nasoseptal flap; SNOT-22, Sinonasal Outcome Test 22.